MX376087B - Inhibidores macrocíclicos de cinasa rip2. - Google Patents
Inhibidores macrocíclicos de cinasa rip2.Info
- Publication number
- MX376087B MX376087B MX2017003469A MX2017003469A MX376087B MX 376087 B MX376087 B MX 376087B MX 2017003469 A MX2017003469 A MX 2017003469A MX 2017003469 A MX2017003469 A MX 2017003469A MX 376087 B MX376087 B MX 376087B
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- macrocyclic
- rip2 kinase
- compounds
- rip2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14185130 | 2014-09-17 | ||
| PCT/EP2015/071347 WO2016042087A1 (en) | 2014-09-17 | 2015-09-17 | Macrocyclic rip2 kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017003469A MX2017003469A (es) | 2017-05-08 |
| MX376087B true MX376087B (es) | 2025-03-07 |
Family
ID=51687776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017003469A MX376087B (es) | 2014-09-17 | 2015-09-17 | Inhibidores macrocíclicos de cinasa rip2. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10676486B2 (enExample) |
| EP (1) | EP3194407B1 (enExample) |
| JP (1) | JP6736545B2 (enExample) |
| KR (1) | KR102563829B1 (enExample) |
| CN (1) | CN106687464B (enExample) |
| AU (1) | AU2015316799B2 (enExample) |
| BR (1) | BR112017004035B1 (enExample) |
| CA (1) | CA2958782C (enExample) |
| DK (1) | DK3194407T3 (enExample) |
| EA (1) | EA032872B1 (enExample) |
| ES (1) | ES2763344T3 (enExample) |
| HR (1) | HRP20192334T1 (enExample) |
| HU (1) | HUE048518T2 (enExample) |
| IL (1) | IL250544B (enExample) |
| LT (1) | LT3194407T (enExample) |
| MX (1) | MX376087B (enExample) |
| MY (1) | MY186523A (enExample) |
| PL (1) | PL3194407T3 (enExample) |
| PT (1) | PT3194407T (enExample) |
| SA (1) | SA517381087B1 (enExample) |
| SG (1) | SG11201701116XA (enExample) |
| SI (1) | SI3194407T1 (enExample) |
| TW (1) | TWI709563B (enExample) |
| UA (1) | UA121315C2 (enExample) |
| WO (1) | WO2016042087A1 (enExample) |
| ZA (1) | ZA201701331B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| CA3168814A1 (en) | 2020-01-31 | 2021-08-05 | Oncodesign S.A. | Macrocyclic rip2-kinase inhibitors |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
| WO2024146541A1 (en) * | 2023-01-03 | 2024-07-11 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Macrocyclic compounds as usp1 inhibitors |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| ES2166786T3 (es) | 1993-10-01 | 2002-05-01 | Astrazeneca Ab | Procedimiento i. |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US7750007B2 (en) * | 2006-11-06 | 2010-07-06 | Supergen, Inc. | Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors |
| AR077468A1 (es) * | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| BR122019024201B1 (pt) | 2010-05-20 | 2021-08-03 | Array Biopharma Inc | Composto macrocíclico como inibidores de trk quinase, seu uso, e composição farmacêutica |
| WO2013001310A1 (en) | 2011-06-30 | 2013-01-03 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Macrocyclic compounds and their use as cdk8 inhibitors |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| MX347765B (es) | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
| PT2760453T (pt) | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
-
2015
- 2015-09-17 AU AU2015316799A patent/AU2015316799B2/en active Active
- 2015-09-17 US US15/505,976 patent/US10676486B2/en active Active
- 2015-09-17 EP EP15766800.5A patent/EP3194407B1/en active Active
- 2015-09-17 ES ES15766800T patent/ES2763344T3/es active Active
- 2015-09-17 SG SG11201701116XA patent/SG11201701116XA/en unknown
- 2015-09-17 HR HRP20192334TT patent/HRP20192334T1/hr unknown
- 2015-09-17 PL PL15766800T patent/PL3194407T3/pl unknown
- 2015-09-17 UA UAA201703558A patent/UA121315C2/uk unknown
- 2015-09-17 MX MX2017003469A patent/MX376087B/es active IP Right Grant
- 2015-09-17 JP JP2017514486A patent/JP6736545B2/ja active Active
- 2015-09-17 CA CA2958782A patent/CA2958782C/en active Active
- 2015-09-17 KR KR1020177010128A patent/KR102563829B1/ko active Active
- 2015-09-17 MY MYPI2017700447A patent/MY186523A/en unknown
- 2015-09-17 DK DK15766800.5T patent/DK3194407T3/da active
- 2015-09-17 LT LTEP15766800.5T patent/LT3194407T/lt unknown
- 2015-09-17 EA EA201790609A patent/EA032872B1/ru unknown
- 2015-09-17 PT PT157668005T patent/PT3194407T/pt unknown
- 2015-09-17 TW TW104130751A patent/TWI709563B/zh active
- 2015-09-17 WO PCT/EP2015/071347 patent/WO2016042087A1/en not_active Ceased
- 2015-09-17 BR BR112017004035-2A patent/BR112017004035B1/pt active IP Right Grant
- 2015-09-17 HU HUE15766800A patent/HUE048518T2/hu unknown
- 2015-09-17 SI SI201531050T patent/SI3194407T1/sl unknown
- 2015-09-17 CN CN201580050163.3A patent/CN106687464B/zh active Active
-
2017
- 2017-02-09 IL IL250544A patent/IL250544B/en active IP Right Grant
- 2017-02-22 ZA ZA2017/01331A patent/ZA201701331B/en unknown
- 2017-03-14 SA SA517381087A patent/SA517381087B1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011359A (es) | Inhibidores macrociclicos de cinasa 2 de repeticion rica en leucina (lrrk2). | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
| MX2019001125A (es) | Inhibidores de cinasa macrociclica. | |
| PH12017501921A1 (en) | Novel compounds | |
| MX2015012528A (es) | Inhibidores macrociclicos de cinasa inducibles por sal. | |
| PH12017500453A1 (en) | Spirocyclic inhibitors of cathepsin c | |
| EA201690159A1 (ru) | Способы и композиции для лечения рака | |
| DOP2017000109A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| TR201904514T4 (tr) | Makrosiklik LRRK2 kinaz inhibitörleri. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| ZA201607489B (en) | Combination comprising a glucocorticoid and edo-s101 | |
| MX2019006863A (es) | Inhibidores de heparanasa y uso de los mismos. | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
| MD4780B1 (ro) | Urei asimetrice p-substituite şi utilizările medicale ale acestora | |
| EA201692020A1 (ru) | Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |